Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world

BACKGROUND: This study aimed to evaluate safety and efficacy of programmed death-1 (PD-1) inhibitor sintilimab plus tyrosine kinase inhibitors (TKI) in a real-word cohort of patients with unresectable hepatocellular carcinoma (uHCC). METHODS: A total of 60 patients treated with sintilimab plus TKI b...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Diyang, Sun, Qiman, Wang, Xiaoying, Zhou, Jian, Fan, Jia, Ren, Zhenggang, Gao, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106062/
https://www.ncbi.nlm.nih.gov/pubmed/33987350
http://dx.doi.org/10.21037/atm-20-7037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106062/
https://www.ncbi.nlm.nih.gov/pubmed/33987350
http://dx.doi.org/10.21037/atm-20-7037

Ejemplares similares